Eli Lilly has announced the success of its Phase 3b Together-PsO trial, demonstrating that combining the obesity medication Zepbound with the autoimmune treatment Taltz provides significantly better outcomes for psoriasis patients who are overweight or obese.
Breakthrough Clinical Results The study involved 274 patients with an average BMI of over 39. After 36 weeks, the results showed:
-
Dual Success: 27% of participants achieved complete skin clearance (PASI 100) and at least 10% weight loss, compared to only 6% of those treated with Taltz alone.
-
Complete Clearance: 41% of those taking the combination achieved total skin clearance, compared to 29% on monotherapy.
[Image showcasing a patient’s journey from chronic inflammation to comprehensive health recovery]
Breaking Down Treatment Silos In the U.S., approximately 61% of people with psoriasis are also overweight or obese. Traditionally, these conditions have been treated in “silos” despite shared underlying inflammatory pathways. Addressing both simultaneously not only improves clinical benchmarks but also optimizes outcomes for high-risk patients who are historically less likely to achieve skin clearance due to high BMI.
Expansion in the Immunology Market This victory, coupled with the previous success of the Together-PsA trial in psoriatic arthritis, allows Eli Lilly to challenge established leaders in the immunology market like AbbVie and Johnson & Johnson. Analysts suggest that Lilly’s immunology franchise may have significant upside as emerging clinical data reinforces the connection between metabolic health and inflammatory diseases.